Use of phospho-Akt as a biomarker of drug response

US10724072B2 · kind B2 · utility

Assignee

• Basilea Pharmaceutica AG · CH

Inventors

• Heidi Lane · Biel-Benken, CH
• Felix Bachmann · Basel, CH

Key dates

• Filing date: May 30, 2018
• Grant date: Jul 28, 2020
• Expiry date: May 30, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Use of phospho-Akt as a biomarker for predicting the response, such as resistance, to a compound, wherein phospho-Akt is Akt that has been phosphorylated on one or more residues, with the proviso that fir Akt1, Akt2, and Akt3 the designation phospho-Akt is used to indicate phosphorylation at a site other than T308, T309 or T305 respectively, wherein the compound is a compound of general formula (I) wherein R represents phenyl, thienyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; X represents a grou…